Dapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review

Among India's 89.8 million people with T2D [1], heart failure incidence reaches approximately 50%, with 33% higher hospitalization risk versus non-diabetics; with undiagnosed HF further adding to this brunt. [2]…

Continue ReadingDapagliflozin and Sitagliptin FDC in T2D with Heart Failure: 2025 Indian Practice Review

High-Dose Influenza Vaccine Benefits Older Adults Regardless of Diabetes: JAMA

Trial results indicate that in adults 65 years and older, the high-dose inactivated influenza vaccine (HD-IIV) consistently reduced cardiorespiratory, cardiovascular, and influenza-related hospitalizations compared with the standard-dose vaccine (SD-IIV), irrespective…

Continue ReadingHigh-Dose Influenza Vaccine Benefits Older Adults Regardless of Diabetes: JAMA